FDA expands use of Actemra to include polyarticular JIA

Genentech received approval from the Food and Drug Administration to market Actemra, or tocilizumab, for children age 2 and older with active polyarticular juvenile idiopathic arthritis. The drug, a humanized interleukin-6 receptor antagonist, can be given alone or with methotrexate. The approval was based on data from a late-stage trial showing that the drug improved symptoms in children with the condition.

View Full Article in:

Medscape (free registration) · BioPharm International online

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
Principal
Visible Men Academy
Bradenton, FL
Director, Department of Defense Dependents Schools, Europe
Department of Defense Education Activity (DoDEA)
Sembach
Program Director, Education and Learning
Urban Libraries Council
Washington, DC
Senior Researcher\/Technical Assistance Consultant (8264)
American Institutes for Research
Washington, DC
K-12 Teachers Needed at Int’l Schools
The International Educator
Multiple Locations